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Background
Tremelimumab is a fully human monoclonal antibody
that binds to CTLA-4 expressed on the surface of acti-
vated T lymphocytes and results in inhibition of B7-
CTLA-4-mediated down regulation of T cell activation.
Both transcatheter arterial chemoembolization (TACE)
and radiofrequency ablation (RFA) have been shown to
induce a peripheral immune response which may
enhance the effect of anti-CTLA4 treatment in patients
with advanced HCC.
Methods
Patients with HCC (Childs Pugh A/B7; Barcelona Clinic
Liver Cancer Stage C; ECOG 0/1; previously progressed
on Sorafenib) are being enrolled in a pilot study of Tre-
melimumab at 2 dose levels (DL1 and DL2) until disease
progression (irRECIST). Subtotal TACE or RFA is per-
formed during study week 6 with DLT evaluation period
encompassing first 8 weeks of study. Tumor tissue is
collected for analysis at baseline on all patients with
optional on-treatment tumor biopsies performed at the
time of the radiologic procedure.
Results
11 pts have been treated so far, 6 pts at DL1 and 5 pts
at DL2; M:F 9:2; Median age = 54(range 42-75);
Cirrhosis present in 7pts. Hepatitis B/C/neg: 3/6/2. 4 pts
received TACE, 7 underwent RFA during week 6 of
Tremelimumab therapy. Tumor tissue is being collected
for analysis at baseline in all patients. Once DL1 was
established as safe and feasible on-treatment tumor
biopsies are being performed at the time of the radiolo-
gic procedure (Day 36 +/- 96hrs) on all patients. So far
2 of 5 patients treated at DL2 have shown extensive
immune cell infiltration on tumor biopsies after 6 weeks
of Tremelimumab. More in depth analysis are currently
being conducted and will be presented together with
safety data.
Conclusions
Tremelimumab in combination with TACE or RFA in
patients with advanced HCC is feasible. Preliminary
pathology data will be presented regarding all post-treat-
ment tumor biopsies.
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